Microbix Boosts STI Testing with New Lab Program
Company Announcements

Microbix Boosts STI Testing with New Lab Program

Microbix Biosystms (TSE:MBX) has released an update.

Microbix Biosystems Inc., a life sciences company, has supported Labquality Ltd. in establishing a new lab accreditation program for molecular tests of drug-resistant sexually-transmitted infections, specifically M. genitalium. Their Quality Assessment Products have proven effective in a pilot program that assessed the proficiency of 38 clinical labs, confirming the need for such external quality assessments in testing. The promising results and availability of Microbix’s innovative control products were showcased at the ECCMID 2024 conference in Barcelona.

For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMicrobix Enhances HPV Testing with New Validation
TipRanks Canadian Auto-Generated NewsdeskMicrobix Unveils Novel HSV Diagnosis Enhancement
TipRanks Canadian Auto-Generated NewsdeskMicrobix Secures Key EU Accreditations for QAPs
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App